Pierrel is an Italian pharmaceutical company with over 70 years of experience in the oral health industry. The company's legal and operational headquarters is in Capua (CE). The production facility was authorized by the EMA (European Medicines Agency) in 1989 and by the FDA (Food and Drug Administration) in 2009 for the production of injectable drugs. Pierrel is one of the leading producers of dental anesthetics marketed under it’s own brands: Ubisestin™, Xylestesin™, Mepivastesin™, and Orabloc; authorized by major international drug regulatory agencies and available in most global markets.

Pierrel's specialization in the dental sector also extends to the research, development, and distribution of medical devices such as GOCCLES (Glasses for Oral Cancer – Curing Light Exposed – Screening), glasses for the early screening of precancerous lesions in the oral cavity, developed at the Catholic University of Rome and awarded for its innovation internationally; Ubigel Inperio, an adhesive regenerating gel used in the treatment of periodontitis for professional use; as well as medical devices complementary to dental anesthesia, such as the Orabloc Needlestick Safety System, which, in compliance with international regulatory requirements, allows one-handed manual recapping, preventing accidental needle sticks from potentially infected needles; Orabloc Dental Needles, made in Italy, needles made of stainless steel with ultra-thin walls, triple-bevel point, and silicone coating; and Pluraject 2, an aspiration syringe that ensures precise control of local anesthesia with a simple and quick cartridges loading system.